17. Biktarvy

biktarvy
Biktarvy is sweeping up patients from Gilead's older HIV meds. (Gilead Sciences)

Biktarvy
Company: Gilead Sciences
2019 sales: $4.74 billion
Projected 2026 sales: $11.4 billion
Projected CAGR: +14%
Used for: HIV

Taking the crown as a drugmaker's best launch ever is no easy feat, but that's exactly what three-drug HIV regiment Biktarvy did for Gilead Sciences in its first full year on the market in 2019. Driven by superior efficacy over older, two-drug therapies, Biktarvy could keep pushing into megablockbuster territory in the coming years.

Biktarvy hit $4.74 billion in sales in 2019 and could post impressive 14% annual growth through 2026, Evaluate Pharma forecast. That increase would put Biktarvy at $11.4 billion in sales by that year, among the biggest hauls in pharma. 

Within Gilead's extensive HIV portfolio, Biktarvy stands out for its three-drug formulation and also its skyrocketing sales, which have bucked a troubling trend for the drugmaker. 

RELATED: Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks

17. Biktarvy

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.